# Table of Contents

## Commentary

**279** Chemoprevention of Squamous Cell Carcinoma of the Head and Neck: No Time to Lose Momentum  
Lori J. Wirth  
See article, p. 283

## Research Articles

**283** Chemoprevention of Head and Neck Cancer with Celecoxib and Erlotinib: Results of a Phase Ib and Pharmacokinetic Study  
See commentary, p. 279

**292** Tazarotene: Randomized, Double-Blind, Vehicle-Controlled, and Open-Label Concurrent Trials for Basal Cell Carcinoma Prevention and Therapy in Patients with Basal Cell Nevus Syndrome  

**300** Raloxifene and Antiestrogenic Gonadorelin Inhibits Intestinal Tumorigenesis by Modulating Immune Cells and Decreasing Stem-like Cells  
Naveena B. Janakiram, Altaf Mohammed, Misty Brewer, Taylor Bryant, Laura Biddick, Stan Lightfoot, Gopal Pathuri, Hariprasad Gali, and Chinthalapally V. Rao

**310** Excess Weight Gain Accelerates 1-Methyl-1-Nitrosourea-Induced Mammary Carcinogenesis in a Rat Model of Premenopausal Breast Cancer  
Shawna B. Matthews, Zongjian Zhu, Weiqin Jiang, John N. McGinley, Elizabeth S. Neil, and Henry J. Thompson

**319** Requirement and Epigenetics Reprogramming of Nrf2 in Suppression of Tumor Promoter TPA-Induced Mouse Skin Cell Transformation by Sulforaphane  
Zheng-Yuan Su, Chengyue Zhang, Jong Hun Lee, Limin Shu, Tien-Yuan Wu, Tin Oo Khor, Allan H. Conney, Yao-Ping Lu, and Ah-Ng Tony Kong

**330** Curcumin: A Double Hit on Malignant Mesothelioma  
Jill M. Miller, Joyce K. Thompson, Maximilian B. MacPherson, Stacie L. Beuschel, Catherine M. Westboom, Mutlay Sayan, and Arti Shukla

**341** Statins and Aspirin for Chemoprevention in Barrett’s Esophagus: Results of a Cost-Effectiveness Analysis  
Sung Eun Choi, Katherine E. Perzan, Angela C. Tramontano, Chung Yin Kong, and Chin Hur

**351** Class I HDACs Are Mediators of Smoke Carcinogen–Induced Stabilization of DNMT1 and Serve as Promising Targets for Chemoprevention of Lung Cancer  
Seth A. Brodie, Ge Li, Adam El-Kommos, Hyunsoek Kang, Suresh S. Ramalingam, Madhusmita Behera, Khanjan Gandhi, Jeannie Kowalski, Gabriel L. Sica, Fadlo R. Khuri, Paula M. Vertino, and Johann C. Brandes

**362** The UK Lung Screen (UKLS): Demographic Profile of First 88,897 Approaches Provides Recommendations for Population Screening  

## Correction

**372** Correction: Interaction of Fatty Acid Genotype and Diet on Changes in Colonic Fatty Acids in a Mediterranean Diet Intervention Study
Estrogen plays an important role in colon tumorigenesis. Studies show that selective estrogen receptor modulators, such as raloxifene, suppress tumor growth. However, gonadorelin, possessing estrogen-modulatory effects, has not been tested on tumor growth. The preventive effects of raloxifene and gonadorelin were studied in female ApcMin/+ mouse intestinal tumorigenesis. Mice treated with raloxifene and gonadorelin showed colon tumor inhibition of 80% and 75%, respectively. As well, these treated tumors showed significantly increased natural killer (NK) cells and chemokines required for NK cells as well as decreased inflammatory genes and cancer stem-like cells (Lgr 5, EpCAM, CD44/CD24). The cover micrograph (60×) depicts the immunohistofluorescence of NK cell receptors (red) and nuclei (blue) in intestinal tumors from ApcMin/+ mice treated with raloxifene and gonadorelin (~4-fold increase; P < 0.002). Both drugs were effective in suppressing tumor growth albeit with different mechanisms. These observations show that either suppression of endogenous estrogen levels (by gonadorelin) or modulation of estrogen receptor (by raloxifene) dramatically suppresses small intestinal and colonic tumor formation in female ApcMin/+ mice and supports the concept of chemoprevention by these agents in reducing endogenous levels of estrogen or modulating ER signaling. See article by Janakiram and colleagues (beginning on page 300) for more information.
Cancer Prevention Research

7 (3)


<table>
<thead>
<tr>
<th>Updated version</th>
<th>Access the most recent version of this article at: <a href="http://cancerpreventionresearch.aacrjournals.org/content/7/3">http://cancerpreventionresearch.aacrjournals.org/content/7/3</a></th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>E-mail alerts</th>
<th>Sign up to receive free email-alerts related to this article or journal.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Reprints and Subscriptions</td>
<td>To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at <a href="mailto:pubs@aacr.org">pubs@aacr.org</a>.</td>
</tr>
<tr>
<td>Permissions</td>
<td>To request permission to re-use all or part of this article, use this link <a href="http://cancerpreventionresearch.aacrjournals.org/content/7/3">http://cancerpreventionresearch.aacrjournals.org/content/7/3</a>. Click on “Request Permissions” which will take you to the Copyright Clearance Center’s (CCC) Rightslink site.</td>
</tr>
</tbody>
</table>